Abstracts tagged "cytokines and psoriatic arthritis"

Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
Qingxuan Song, Matthew Loza, Karen Leander, Brittney Scott, Patrick Branigan and Kristen Sweet, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…
Abstract Number: 1792 • 2017 ACR/ARHP Annual Meeting
Distinct and Overlapping Activities of IL-17A and TNF on the Expression of Proinflammatory Cytokines and MMPs in Psoriatic Arthritis: Rationale for Anti-IL-17A/Anti-Tnfalpha Combination Therapy?
Xiaofei Xu¹, Nadine Davelaar², Anne-Marie Otten-Mus³, Patrick Asmawidjaja², J.M.W. Hazes⁴, Dominique Baeten⁵, Marijn Vis⁶, Radjesh Bisoendial¹ and Erik Lubberts², ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: TNF and IL-17A are proinflammatory cytokines critically involved in the pathogenesis of psoriatic arthritis (PsA). Currently, targeting TNF is the first choice of a…
Abstract Number: 1670 • 2016 ACR/ARHP Annual Meeting
Cytokine Expression in Groups of Psoriatic Arthritis Patients Characterised By Specific HLA Genotypes and Clinical Features
Musaab Elmamoun¹, Wilco de Jager², Sytze de Roock³, Muhammad Haroon⁴, Robert Winchester⁵, Stephen R. Pennington⁶ and Oliver FitzGerald⁷, ¹Rheumatology, St. Vincent's University Hospital, Department of Rheumatology, Dublin 4, Ireland, ²Dept Immunology, UMC Utrecht, Utrecht, Netherlands, ³Immunology, University Medical Center, Utrecht, Netherlands, ⁴St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁶Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ⁷St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease with diverse clinical and radiographic manifestations. A number of human leukocyte antigen (HLA) alleles have been found…
Abstract Number: 1598 • 2014 ACR/ARHP Annual Meeting
Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis
Hanna Przepiera-Bedzak¹, Katarzyna Fischer² and Marek Brzosko¹, ¹Department of Rheumatology and Internal Diseases, Department of Rheumatology and Internal Diseases Pomeranian Medical University in Szczecin, Szczecin, Poland, ²Independent Laboratory of Rheumatic Diagnostics, Pomeranian Medical University in Szczecin, Szczecin, Poland
Background/Purpose In recent years, increased incidences of metabolic disorders have been observed in patients with systemic inflammatory rheumatic diseases. Fetuin-A, Intercellular Adhesion Molecule -1(ICAM-1) and…
Abstract Number: 633 • 2014 ACR/ARHP Annual Meeting
Immunological and Clinical Relationships of Synovial IL-17+ T Cells in Psoriatic Arthritis
Bruce Kirkham¹, Bina Menon² and Leonie S. Taams³, ¹Rheumatology, Guy's & St Thomas NHS Foundation Trust, London, United Kingdom, ²Rheumatology, Guy's and St. Thomas' Foundation Hospital NHS Trust, London, United Kingdom, ³Centre for Molecular and Cellular Biology of Inflammation, King's College London, London, United Kingdom
Background/Purpose We recently reported elevated numbers of synovial fluid IL-17+CD4- T cells (mainly CD8+ (Tc17) cells) in Psoriatic Arthritis (PsA), correlating with clinical, serological and…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.